Liposomal Formulation Enhances Pharmacokinetics of Jaspine B in Cancer Gene Therapy

Strategic Insights -

Researchers from Idaho State University have made significant breakthroughs in cancer gene therapy, leveraging a liposomal delivery system to enhance the pharmacokinetics of Jaspine B, a synthetic analog of anhydrophytosphingosine. This innovative approach has demonstrated improved therapeutic outcomes, with the liposomal formulation accelerating the absorption of Jaspine B and prolonging its body circulation and exposure.

Key Takeaways:

  • Jaspine B, a synthetic analog of anhydrophytosphingosine, has shown significant anticancer activity, but its clinical application is hindered by poor oral bioavailability.
  • A liposomal delivery system was developed to enhance the pharmacokinetic properties of Jaspine B, resulting in improved systemic exposure and therapeutic outcomes.
  • The liposomal formulation accelerated the absorption of Jaspine B, reaching the maximum concentration (Tmax) at 2 hours as opposed to 6 hours in plain Jaspine B.
  • The half-life (t1/2) of Jaspine B increased significantly from 7.9 ± 2.3 hours to 26.7 ± 7.3 hours, indicating prolonged body circulation.
  • The area under the curve (AUC0-) increased over two-fold from 56.8 ± 12.3 ng.h/mL to 139.7 ± 27.2 ng.h/mL, suggesting increased systemic drug exposure.
  • The mean residence time (MRT) of Jaspine B increased over three-fold, indicating improved pharmacokinetics of the liposomal formulation.
  • The study demonstrated that liposomal formulation of Jaspine B enhances its pharmacokinetics, prolonging its body circulation and exposure, which explains the improved therapeutic outcomes observed in previous pharmacodynamic studies.
  • The research concluded that the liposomal formulation is a promising approach for cancer gene therapy, with potential applications in improving the efficacy of anti-cancer drugs.
  • The study highlights the importance of liposomal delivery systems in enhancing the pharmacokinetics of anticancer drugs, leading to improved therapeutic outcomes.
  • The research has significant implications for the development of cancer gene therapy, with potential applications in improving the efficacy and safety of anti-cancer drugs.

Statistics:

  • Tmax: 2 hours
  • Tmax (plain Jaspine B): 6 hours
  • Half-life (t1/2) of Jaspine B: 26.7 ± 7.3 hours (liposomal formulation)
  • Half-life (t1/2) of plain Jaspine B: 7.9 ± 2.3 hours
  • AUC0- (liposomal formulation): 139.7 ± 27.2 ng.h/mL
  • AUC0- (plain Jaspine B): 56.8 ± 12.3 ng.h/mL
  • MRT (liposomal formulation): increased over three-fold
  • Systemic exposure (liposomal formulation): increased over two-fold

Sources:

  • NewsRx. Idaho State University Researchers Highlight Recent Research in Cancer Gene Therapy (Comparative Bioavailability Study of Jaspine B: Impact of Nanoliposomal Drug Delivery System on Pharmacokinetics). Cancer Weekly. August 12, 2025; p 30.
  • Comparative Bioavailability Study of Jaspine B: Impact of Nanoliposomal Drug Delivery System on Pharmacokinetics. Pharmaceutics, 2025,17(7):807. (Pharmaceutics - http://www.mdpi.com/journal/pharmaceutics/). The publisher for Pharmaceutics is MDPI AG.
  • https://doi-org.sdpl.idm.oclc.org/10.3390/pharmaceutics17070807.